Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 17/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.71 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.71 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.52 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.52 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803671 | 0.89 | PIK3CA (0.64) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL18616748 | 0.83 | PIK3CA (0.61) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL924512 | 0.82 | PIK3CG (0.61) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL571452 | 0.82 | PIK3CA (0.69) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1939012 | 0.79 | PIK3CD (0.58) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL10670937 | 0.79 | PIK3CG (0.72) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL942547 | 0.78 | PIK3CA (0.61) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL3491367 | 0.78 | PIK3CA (0.55) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1938991 | 0.78 | PIK3CD (0.56) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL23876299 | 0.77 | PIK3CA (0.54) | PIK3CGPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-20180318275-A1 | COMBINATION THERAPY USING PI3K INHIBITOR AND MDM2 INHIBITOR | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-11-08 | — | — | US | disclosed |
| US-20180256557-A1 | PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180243280-A1 | A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180243279-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2017037586-A1 | COMBINATION THERAPY USING PI3K INHBITOR AND MDM2 INHIBITOR | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037573-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| WO-2012016970-A1 | A CRYSTALLINE FORM OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4 -METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL)-AMIDE AND ITS USE AS PI3K INHIBITOR | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012016970-A1 | A CRYSTALLINE FORM OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4 -METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL)-AMIDE AND ITS USE AS PI3K INHIBITOR | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010029082-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243279-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | BRAF, RAF1, PIK3CA | PIK3CG 16/4885PIK3CA 3/4885PIK3CD 12/4885 |
| US-20180243280-A1 | A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | CDK4, CDK3, CDK6 | PIK3CG 42/4885PIK3CA 13/4885PIK3CD 38/4885 |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | CDK4, CDK6, CDK9 | PIK3CG 20/4885PIK3CA 5/4885PIK3CD 15/4885 |
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PIK3CG 8/4885PIK3CA 2/4885PIK3CD 3/4885 |
| US-20180318275-A1 | COMBINATION THERAPY USING PI3K INHIBITOR AND MDM2 INHIBITOR | TP53, MDM2, BCL2 | PIK3CG 42/4885PIK3CA 24/4885PIK3CD 32/4885 |
| US-20180256557-A1 | PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | PIK3CA, PIK3R5, PIK3R2 | PIK3CG 13/4885PIK3CA 1/4885PIK3CD 7/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PIK3CG 7/4885PIK3CA 2/4885PIK3CD 3/4885 |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | BRAF, RAF1, PIK3CA | PIK3CG 16/4885PIK3CA 3/4885PIK3CD 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.